Form D · Pharmaceuticals
FibroBiologics, Inc.
Houston, TX · CIK 0001958777
Offering snapshot reported Oct 13, 2026 · SEC filing
- Reported sold
- $1.2M Offering amount: $1.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 7, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 13, 2026 | Initial | $1,200,000 | No comparison | 1 | SEC filing |
| Sep 16, 2026 | Initial | $500,001 | No comparison | 1 | SEC filing |
| Jun 29, 2026 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Dec 16, 2025 | Initial | $1,725,001 | No comparison | 4 | SEC filing |
| Dec 3, 2025 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
| Dec 3, 2025 | Initial | $1,500,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-600820
Includes a convertible debenture in the principal amount of $1,200,000 and 125,000 restricted shares. The debenture is convertible following an event of default at a fixed conversion rate of $0.78 per share.
Source: Form D, filed Oct 13, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard C. Cilento | Director |
| Stacy Coen | Director |
| Jason D. Davis | Executive |
| Ruben A. Garcia | Executive |
| Robert Hoffman | Director |
| Hamid Khoja | Executive |
| Matthew Link | Director |
| Victoria Niklas | Director |
| Pete O'heeron | Director, Executive |
| Kathleen H. Rubins | Director |
| Leigh Steinberg | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
9350 Kirby Drive Suite 300
Houston, TX, 77054
Houston, TX, 77054